77242113PSO3006: A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ 77242113 for the Treatment of Participants With Moderate to Severe Plaque Ps
77242113PSO3006: A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ 77242113 for the Treatment of Participants With Moderate to Severe Plaque Ps
The main purpose of this study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to severe plaque psoriasis.
Inclusion Criteria:
Exclusion Criteria:
Fort Gratiot, Michigan 48059, United States
Barrio Gral Paz Cba Capital, X5000, Argentina
CABA, C1055AAO, Argentina
CABA, C1056ABH, Argentina
CABA, C1061AAS, Argentina
Caba, C1122AAF, Argentina
CABA, C1128, Argentina
CABA, C1199ABB, Argentina
St. John's, Newfoundland and Labrador A1E 1V4, Canada
Elblag, 82 300, Poland
Krakow, 30 002, Poland
Santiago Compostela, 15706, Spain